Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Dosimetry Analysis of <sup>177</sup>Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Phase 2 Prospective Trial of Retreatment with [<sup>177</sup>Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma.

Current oncology (Toronto, Ont.)·2025

Related Experiment Video

Updated: Jul 11, 2026

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

18F-FDOPA kinetics in brain tumors.

Christiaan Schiepers1, Wei Chen, Timothy Cloughesy

  • 1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA. cschiepers@mednet.ucla.edu

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|September 18, 2007
PubMed
Summary

This study investigated L-3,4-Dihydroxy-6-(18)F-fluoro-phenyl-alanine ((18)F-FDOPA) kinetics in brain tumors. A 3-compartment model adequately described uptake, differentiating tumor grades by kinetics, aiding in diagnosis.

More Related Videos

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
08:36

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Related Experiment Videos

Last Updated: Jul 11, 2026

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET
09:03

Radiotracer Administration for High Temporal Resolution Positron Emission Tomography of the Human Brain: Application to FDG-fPET

Published on: October 22, 2019

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
09:58

Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury

Published on: November 9, 2018

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
08:36

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

Area of Science:

  • Neuroimaging
  • Radiochemistry
  • Oncology

Background:

  • L-3,4-Dihydroxy-6-(18)F-fluoro-phenyl-alanine ((18)F-FDOPA) is an amino acid analog used for evaluating presynaptic dopaminergic neuronal function and detecting tumor recurrence in neurooncology.
  • Understanding the kinetic behavior of (18)F-FDOPA in brain tumors is crucial for accurate diagnosis and treatment monitoring.

Purpose of the Study:

  • To investigate the kinetics of (18)F-FDOPA in various grades of brain tumors using positron emission tomography (PET).
  • To evaluate the suitability of different compartmental models for describing (18)F-FDOPA uptake in tumors and normal brain structures.
  • To correlate kinetic parameters with tumor grade and differentiate between tumor types.

Main Methods:

  • Dynamic PET imaging was performed on 37 patients with brain tumors (grades II-IV), metastases, or benign lesions after (18)F-FDOPA administration.
  • Data analysis involved iterative image reconstruction, corrections for attenuation and scatter, and factor analysis to derive input and output functions.
  • Compartmental modeling, including 2- and 3-compartment models with corrections for tissue blood volume, metabolites, and partial volume, was applied to estimate kinetic rate constants.

Main Results:

  • A 3-compartment model provided a superior description of (18)F-FDOPA kinetics in tumors and the striatum compared to a 2-compartment model.
  • Significant correlations were observed between the influx rate constant (K) and late tumor uptake (SUV 65-75 min).
  • High-grade tumors exhibited significantly higher transport rate constant (k(1)), distribution volumes, and influx rate constant (K) than low-grade tumors. Logan graphical analysis effectively distinguished between newly diagnosed high-grade and low-grade tumors.

Conclusions:

  • A 3-compartment model, incorporating corrections for metabolites and partial volume, adequately describes (18)F-FDOPA kinetics in brain tumors, striatum, and cerebellum.
  • (18)F-FDOPA is transported but not trapped in tumors, contrasting with its behavior in the striatum.
  • The shape of the (18)F-FDOPA uptake curve correlates with tumor grade, with high-grade tumors showing a steep decline after an early peak, unlike the slowly declining curve in low-grade tumors.